Advanced Breast Cancer Burden
- Despite the difference in incidence rates of BC between developed and developing countries, the disease remains the most common type of female cancer in Egypt with an age-specific incidence rate of 48.8/105. Approximately 46,000 incident cases are forecasted in 2050.1
- When comparing the mortality/incidence rate ratio for BC between Egypt and developed countries, Egypt had approximately double the ratio (41% Vs 23%). Moreover, it is currently the second most common cause of Egyptian cancer mortality after hepatocellular carcinoma with estimated mortality rate around 11% in 2020.1
Mortality/ incidence rate ratio
Developed countries
Reference 1
In Egypt 2023, Among 9,738 patients with BC
Reference 1
About HR+/HER2− advanced breast cancer
- Breast cancer can be categorized according to molecular subtype and stage of disease.2
- Advanced breast cancer (aBC) describes both locally advanced and metastatic disease.3
- Around 75% of aBC patients have hormone receptor-positive (HR+) tumours, with about 70% of these patients also having human epidermal growth factor receptor 2-negative (HER2−) tumours.5
HR+/HER2: Hormone Receptor-Positive/Human Epidermal Growth Receptor.
References
Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis, Hamdy A. Azim,et al. American Society of Clinical Oncology, 2023.
Carvalho E, Canberk S, Schmitt F, Vale N. Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies. Cancers. 2025 Mar 25;17(7):1102.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L. 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). The Breast. 2017 Feb 1;31:244-59. Brest cancer statistics and resources. Available at: https://www.bcrf.org/breast-cancer-statistics-and-resources/; last accessed: 9/3/2025.
National cancer institute. Cancer Stat Facts: Female Breast Cancer Subtypes. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html; last accessed: 9/9/2025.
El Sayed R, El Jamal L, El Iskandarani S, Kort J, Salam MA, Assi H. Endocrine and targeted therapy for hormone-receptor-positive, HER2-negative advanced breast cancer: insights to sequencing treatment and overcoming resistance based on clinical trials. Frontiers in oncology. 2019 Jun 21;9:510.
Adverse Events Reporting We encourage using the following Electronic reporting tool for reporting into the safety database directly: |